Home > Insider Trading > Filing (0000899243-18-019455)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1693415	Translate Bio Inc.	TBIO	Biological Products, (No Disgnostic Substances) (2836)	611807780

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1709976	Jr. M. Brian Gallagher	C/O S.r. One, Limited 161 Washington Street, Suite 500 Conshohocken PA 19428		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-07-02	1,674,016	$0.00	1,674,016	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2018-07-02	1,300,116	$0.00	2,974,132	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2018-07-02	454,550	$0.00	3,428,682	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2018-07-02	269,230	$13.00	3,697,912	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2018-07-02	9,300,000	$0.00	1,674,016	$0.00
Common Stock	Series B Preferred Stock	Disposition	2018-07-02	7,222,797	$0.00	1,300,116	$0.00
Common Stock	Series C Preferred Stock	Disposition	2018-07-02	2,525,253	$0.00	454,550	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Reflects shares of the Issuer's Common Stock that were purchased in connection with the Issuer's initial public offering.
The Series A, Series B and Series C Preferred Stock were converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of these shares reported herein. Brian M. Gallagher, Jr. is a Partner and Vice President at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Mr. Gallagher disclaims beneficial ownership of all shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purpose of Section 16 or for any other purpose except to the extent of his pecuniary interest therein.